TELO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.8M
+69.5%
1.0M
-51.2%
2.1M
+86.2%
1.1M
-77.4%
5.1M
R&D
444.7K
-4.9%
467.8K
-63.9%
1.3M
+70.7%
759.5K
+1673.0%
42.8K
SG&A
1.3M
+130.2%
573.5K
-31.6%
838.5K
+116.7%
387.0K
-92.3%
5.0M
Operating Income
-1764676
-69.5%
-1041336
+51.2%
-2134681
-86.2%
-1146476
+77.4%
-5069910
EBITDA
-1764676
-69.5%
-1041336
+51.2%
-2134681
-86.2%
-1146476
+77.4%
-5069910
Net Income
-1721528
-73.7%
-990947
+51.9%
-2061193
-87.0%
-1102294
+78.3%
-5069890
EPS (Basic)
$-0.79
-2533.3%
$-0.03
+50.0%
$-0.06
-100.0%
$-0.03
+82.4%
$-0.17
EPS (Diluted)
$-0.79
-2533.3%
$-0.03
+50.0%
$-0.06
-100.0%
$-0.03
+82.4%
$-0.17
Shares (Diluted)
60.8M
+77.0%
34.4M
-0.2%
34.4M
+6.3%
32.4M
+8.0%
30.0M
Telomir Pharmaceuticals (TELO) โ€” Financials